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Efforts of this research project resulted in diverse advances in (a) synthesis of new
radiotracers for neurochemical studies, (b) evaluation of microPET imaging to uncover
unusual transient effects of drugs, (c) development of new radiotracers to investigate
biochemistry of cancers, (d) human studies using single-session dual-radiotracer imaging
paradigms, and (e) continued development of improved image processing and analysis
methods.  
Evaluation of 1-[18F]fluoroethyl analogs of cholinesterase substrates.  We
prepared a series of [18F]fluoroethyl compounds analogous to N-[11C]methyl-4-piperidinyl
acetate ([11C]PMP) and determined the in vitro cleavage rates in purified AChE and
BuChE, rate of metabolism in mouse blood, ex vivo biodistribution in mouse brain and in
vivo the behavior in rats measured by microPET imaging. Four candidate radiotracers,
(S)-N-fluoroethyl-2-piperidinemethyl acetate (1), (R)-N-fluoroethyl-3-pyrrolidinyl acetate
(2), N-fluoroethyl-4-piperidinyl acetate (3) and (R)-N-fluoroethyl-3-piperidinyl acetate
(4), were evaluated. Compound 1 showed rapid metabolism in mouse blood, relatively
fast regional brain pharmacokinetics and poor discrimination between brain regions with
different AChE concentration (striatum versus cortex). Compound 4 showed relatively
slower blood metabolism and slower pharmacokinetics than compound 1, but again poor
discrimination between brain regions. Compound 3 had the slowest blood metabolism
and pharmacokinetics too slow to be practical for imaging. Compound 2 showed highly
encouraging characteristics with an in vivo metabolism rate slower than [11C]PMP,
similar primate brain uptake and pharmacokinetics to [11C]PMP, and good discrimination
between brain regions.
Development of HPLC methods for measuring log kW and analysis of model
compounds. We have developed a standard HPLC method for predicting blood-brain
barrier permeation of tracer candidates, based on tracer lipophilicity under physiological
conditions.  Many radiotracer molecules contain ionizable functional groups (such as
amines), and the HPLC system used must mimic physiological pH and ionic strength to
be an accurate index of BBB permeation. After testing a variety reversed-phase and ion-
pairing HPLC columns, and numerous combinations of solvents and buffer salts, we
settled on a standard Ultremex 5µm C18 column (4.6 x 250 mm) and a mixture of
acetonitrile and 100 mM 3-(N-morpholino)propanesulfonic acid (MOPS) buffer at pH
7.4.  This system allows analysis of a wide range of compounds at UV wavelengths as
low as 220 nm, and was then used to measure the capacity factor of several test
compounds at three different solvent mixtures (i.e. % acetonitrile). The mean capacity
factor (k) at each solvent strength (n=3-5) was determined, where k = (tR - t0)/t0, and t0 is
the column dead time based on the elution time of methanol as an unretained species.
The log k values in each solvent mixture were then plotted versus % acetonitrile and
extrapolated to provide log kW, the capacity factor at 0% acetonitrile.  The log kW values
of dihydrotetrabenazine (DTBZ), flumazenil (FMZ), phenethylamine, tyramine and
methyl 1-methylisonipecotate have been measured. So far, there is no correlation with
reported (or calculated) log P values, however several more compounds will need to be
analyzed before valid correlations with lipophilicity (log P) or BBB permeation (as
measured by initial brain uptake of radiotracers in rodents) can be determined.
MicroPET: Effects of anesthesia on in vivo neurochemical measures.  One
goal of this project is to measure the changes in trafficking of the dopamine transporter
via manipulations of the cholinergic system. The use of microPET as the analytical
method to measure cholinergic drug-induced changes requires (1) demonstration that
anesthesia, currently required for routine small animal microPET studies, does not
interfere with the drug-induced biochemical changes, and (2) that microPET is capable of
measuring small changes in radiotracer binding. We have thus completed a study
comparing the drug induced changes in the binding of a muscarinic cholinergic
antagonist radioligand, N-[11C]methylpyrrolidinylbenzilate (NMPYB), in awake and
anesthetized animals using both microPET and classical tissue dissection techniques.  All
ex vivo dissection studies were done using the previously established bolus+infusion
method of radiotracer administration, which allows determination of equilibrium
distribution volume ratios (DVR) in regions of interest such as the striatum, cortex and
hippocampus (cerebellum used as reference region for nonspecific distribution).  In both
the awake and anesthetized state, we found that administration of the acetylcholinesterase
inhibitor phenserine induced a 9-11% decrease in the in vivo specific binding of
[11C]NMPYB in the striatum (control DVR = 6.84 +/- 0.32; phenserine-treated 6.29 +/-
0.41, P < 0.05) and cortex (control DVR = 5.36 +/- 0.15; phenserine treated 4.79 +/- 0.36,
P < 0.05).  These small changes were evident with a relatively small number of animals
per experimental group (N = 4 or 5).  It was thus clear that anesthesia does not interfere
with the actions of an acetylcholinesterase inhibitor to raise brain acetylcholine levels in
the rat.
When this experiment was performed using the microPET as the instrument of
analysis, it was not possible to measure the expected decrease in binding of
[11C]NMPYB.  Studies were done using bolus injection of radiotracer, imaging of
radiotracer distribution for one hour, and pharmacokinetic modeling of the regional tissue
time-activity curves using a reference region Logan plot using the cerebellum as the
reference tissue.  There were no significant differences seen between control (striatal
DVR = 2.80 +/- 0.37, N = 5) and phenserine-treated animals (striatal DVR = 3.10 +/-
0.42, N = 5).  As we had shown that the anesthesia needed for the microPET studies
should not have interfered, our conclusion is that the microPET method was not sensitive
enough to measure small (10%) changes in radiotracer binding in a reasonably small
group of animals.  It remains undetermined if small changes in radiotracer binding might
be measured using a large number of animals.
We then examined the in vivo binding of N-[18F]fluoroethyl-piperidinyl benzilate
([18F]FEPB) to the muscarinic cholinergic receptor was measured in awake and
anesthetized rats. Studies were done using an equilibrium infusion technique to provide
estimates of specific binding as distribution volume ratios. Anesthesia with either
isoflurane or sodium pentobarbital produced a significant (65-90%) increase of
radiotracer binding in receptor-rich brain regions (striatum, cortex, hippocampus) relative
to awake controls.   Pretreatment of anesthetized animals with the acetylcholinesterase
inhibitor phenserine produced no further increases in radioligand binding, in contrast to
the large (>70%) increases previously observed in awake animals following drug
treatment.  These studies demonstrate that anesthesia can produce significant changes in
baseline biochemical measures that can obscure even very large effects of
pharmacological challenges.
MicroPET: Imaging partial lesions of the striatal dopaminergic system.  The
ability of the microPET to differentially image and quantify dopaminergic terminal loss
in partially-lesioned rat striata was evaluated 8 animals.  All received partial 6-
hydroxydopamine lesions of the right medial forebrain bundle (MFB), producing
unilateral lesions in the contralateral striatum. Each animal was then imaged using
[11C]dihydrotetrabenazine (DTBZ) and microPET. Using bolus injection of the
[11C]DTBZ, one hour of imaging, and Logan plot analyses, distribution volume ratios for
right and left striata were obtained.   There was a consistent (8/8 animals) reduction in
striatal DVR on the lesioned side of all animals: control striatal DVR = 6.18 +/- 0.79;
lesioned striatal DVR = 5.54 +/- 1.05, P < 0.01 paired t-test).  The average loss of binding
of about 10% (lesioned/control = 0.89 +/- 0.08; range 0.72 to 0.95).
Scopolamine: Differential effects on monoamine transporters. We have
studied the effects of scopolamine, a muscarinic cholinergic antagonist, on the in vivo
binding of radiotracers for transporters in monoaminergic neurons.  We had previously
found that scopolamine increased [3H]methylphenidate binding to the DAT (controls,
striatal DVR = 2.11 +/- 0.15; scopolamine-treated, DVR = 2.44 +/- 0.25, p < 0.05), and
hypothesized that this was due to a indirect effect of scopolamine on intracellular levels
of protein kinase C.  We have now shown that scopolamine does not have any effect on
in vivo binding of  [11C]DTBZ  to the VMAT2 (controls, striatal DVR = 3.29 +/- 0.23;
scopolamine-treated, DVR = 3.39 +/- 0.48, p > 0.50).  This is consistent with our
hypothesis that VMAT2 is not a regulated transporter, and supports that the changes seen
in the methylphenidate study were not due to such as altered blood flow.
Dual Radiotracer Studies: Enhancement of sensitivity to biochemical
changes. Using a data set for simultaneous [11C]DTBZ (VMAT2 radioligand) and
[3H]methylphenidate (DAT radioligand) equilibrium infusions, the ratio of striatal DVR
ratios for [3H]methylphen/[11C]DTBZ was calculated for control animals as well as
animals treated with a dopamine antagonist  and a dopamine agonist. In control animals,
the ratio in control animals was 0.54 +/- 0.02. In haloperidol treated animals, the ratio
was 0.52 +/- 0.04. The apomorphine-treated  animals showed a ratio of 0.74 +/- 0.21, a
significant change relative to controls (P = 0.04) and haldol-treated animals (P = 0.03).
The observed increase in the methylphen/DTBZ ratio could correspond to an increase in
DAT availability, and this would fit our proposed model of trafficking of the DAT
between cytosolic and external membrane locations.
Drug sensitivity of VMAT2 and DAT radioligand binding: dopamine
depletion. We have completed a study of the effects of dopamine depletion  on
differential drug sensitivity of DAT and VMAT2 radioligands in normal rat brain. The
sensitivity of the in vivo binding of [11C]dihydrotetrabenazine and [11C]methylphenidate
to their respective targets, the vesicular monoamine transporter (VMAT2) and the
neuronal membrane dopamine transporter (DAT), after alterations of endogenous levels
of dopamine were examined in the rat brain.  Repeated dosing with α-methyl-p-tyrosine
(AMPT) at doses sufficient to nearly completely deplete dopamine levels resulted in
increased (+26%) in vivo [11C]dihydrotetrabenazine binding in the striatum.  The increase
in binding could be reversed by treatment with L-DOPA/benserazide to restore dopamine
levels.  There were no changes in total numbers of vesicular monoamine transporter
binding sites as measured using in vitro autoradiography.  No changes were observed for
in vivo [11C]methylphenidate binding to the dopamine transporter in the striatum
following α-methyl-p-tyrosine pretreatment.  These results indicate that large changes of
dopamine concentrations in the rat brain can produce small but significant changes in
binding of radioligands to the vesicular monoamine transporter.
MicroPET imaging of dynamic effects of AMPT on [11C]DTBZ binding. The
ability of microPET imaging to measure the above changes in [11C]DTBZ bidning after
AMPT treatment was evaluated.  The equilibrium infusion protocol for radiotracer
administration was first validated in a set of control animals (N = 14) to provide a
composite tissue time-radioactivity curve with stable striatum-to-cerebellum ratios for the
period of 45-90 minutes. At equilibrium this ratio (2.84) represents the distribution
volume for the striatum, a measure of the specific binding. Surprisingly, injection of
AMPT at 40 minutes after beginning the radioligand infusion into a second set of animals
(N = 14) produced an unusual initial decrease in the str/cbl ratios lasting for 15 minutes,
after which the str/cbl ratios rose and at the end of the study were equivalent (2.82) to the
control animals. This effect of AMPT was significantly different than had been observed
in earlier dissection experiments.
 
The transient decrease of the tissue time-radioactivity curves following AMPT injection,
seen for every animal, remains puzzling and unexplained. In almost all cases, animals
were done in pairs (one control, one AMPT-treated) to remove confounding effects of
different radiochemical preparations, and scanners (microPET R4 and P4) randomized to
remove that confound. The transient changes were not seen with injection of other
dopaminergic drugs, such as haloperidol and clorgylline. The transient inflection in the
curve was not seen upon AMPT administration during an infusion of
[11C]methylphenidate, a dopamine transporter (DAT) radioligand. This unusual behavior
of the [C-11]DTBZ upon acute severe depletion of dopamine levels continues to be under
study.  
 
PepT1 transporter activity as a target for tumor imaging in pancreatic cancer with
[C-11]Glycylsarcosine ([C-11]Gly-Sar).Pancreatic cancer is one of the most aggressive
human tumors, with a 5 year survival rate of only 3-5% and a median survival of less
than 6 months. Early detection and accurate staging are critical for effective management
and optimal treatment planning in this disease. However, none of the currently available
PET radiopharmaceuticals are useful for imaging pancreatic cancer. The proton-coupled
di/tri-peptide transporter, PEPT1 is highly expressed in a number of immortalized human
tumor cell lines, including several pancreatic adenocarcinoma lines. Recent work in this
project has focused on determining the utility of measuring expression of the PEPT1
proton-coupled di/tri-peptide transporter in the diagnosis, staging and therapy planning in
adenocarcinoma of the pancreas. Preliminary tumor imaging studies were performed with
the radiolabeled PEPT1 substrate, [C-11]Gly-Sar in four pancreatic (AsPC-1, Capan-2,
MPanc-96 and PANC-1) and one prostate (PC-3) adenocarcinoma cell lines expressing a
range of PEPT1 activity. The initial uptake of [C-11]Gly-Sar in the various tumor types,
measured by ex vivo dissection and counting methods, agreed with the rank order of
PEPT1 expression measured in vitro by RT-PCR and Western blot analysis. By 60
minutes post-injection differences in tracer retention were statistically significant
between the high (MPanc-96, AsPC-1, and Capan-2) and low (PANC-1 and PC-3)
PEPT1 expression groups (p < 0.001). However, all tumors retained radioactivity 1.5
(PC-3) to 3-fold (MPanc, AsPC-1) above blood levels at this later time point. Dual tracer
([C-11]Gly-Sar/[F-18]FDG) imaging experiments were also consistent with in vitro
PEPT1 expression measurements. MPanc-96 showed highest retention of radioactivity,
followed by AsPC-1 and Capan-2. PANC-1 and PC-3 tumors exhibited the lowest
radioactivity. These differences between high (MPanc-96), intermediate (AsPC-1, Capan-
2) and low (PANC-1, PC-3) [C-11]Gly-Sar retention were statistically significant
(p(High/Mid) = 0.08, p(Mid/Low) < 0.005). The [F-18]FDG retention in these tumor
lines was uniformly higher than that of [C-11]Gly-Sar and exhibited an equally large
variance between individual tumors. Differences in the [F-18]FDG retention between
tumors were obvious in this series, however as expected these differences do not appear
to correlate with PEPT1 activity. Taken together this set of in vitro, ex vivo and in vivo
experiments provide strong evidence that [C-11]Gly-Sar uptake and retention in tumors is
mediated by PEPT1 transport. Furthermore, it should be possible to measure moderate
differences between PEPT1 activity levels in vivo with PET. This represents a novel new
method for imaging and potential biochemical characterization of pancreatic tumors.  
Dual Radiotracer Overlapping Studies: Human PET studies. The general aim of
this project is to estimate multiple neuropharmacological parameters within a single non-
invasive positron emission tomography (PET) procedure.  The significance of this
research centers on the concept that rather than examining particular aspects of the
working brain in isolation, we would like to provide a broader more global view of
cerebral function. We investigated an experimental protocol for dual-injection, single-
acquisition PET scans that does not require arterial blood sampling. We have performed a
variety of computer simulations to determine how best to estimate model parameters
from a dual-injection study without the use of measured arterial input functions.  The
procedure has several steps including the use of various reference region-type
calculations (Logan plots, reference tissue model), some with limited temporal ranges of
data. The simulations performed so far have given us an idea of how much additional
variability to expect in the estimates of the parameters for both tracers, relative to single-
tracer studies.  We have also been working on ways to improve precision through various
constraints or estimation parameters across multiple regions simultaneously.
A total of 76 subjects have received dual-tracer PET studies performed using three
different combinations of radiotracers; i) [C-11]flumazenil (FMZ) with [C-
11]dihydrotetrabenazine (DTBZ); and ii) [C-11]FMZ with N-[ C-11]methylpiperidinyl
propionate (PMP) and [C-11]raclopride (RAC) with [C-11]methylphenidate (MPH). The
first and third combinations of radiotracers each involve one tracer with rapidly reversible
kinetics (FMZ or RAC) and one with moderate kinetics (DTBZ or MPH), but still
reversible kinetics. The second pair involves one tracer with rapidly reversible kinetics,
but the second (PMP) with irreversible kinetics (i.e. k4=0). In the first two years of the
grant, both a dual-tracer and a single-tracer PET study were been performed on each
individual for comparison and validation of the dual-tracer results using the single-tracer
study as a gold standard. Subsequently two dual-tracer studies have been performed on
each subject, separated in time by one day up to one week. These studies involve one
baseline dual-tracer scan and one scan acquired under a condition of partial blocking of
one of the tracers (FMZ) with a non-radioactive antagonist (Romazicon). The purpose of
these studies is to validate that the kinetic model parameters change significantly between
scans only for the tracer whose uptake is blocked by the antagonist (FMZ), while the
other tracer (either DTBZ or PMP) parameters are statistically unchanged. In the past
year of the project 28 of these subjects have had two dual-tracer scans performed. Results
show both good sensitivity to the antagonist-induced changes in binding in the one tracer
and good specificity where the other tracer was unaffected.  
 
The key to good performance of a non-invasive dual-tracer PET protocol is the separation
of the two tracer components of the total PET uptake curves. New methods to separate
these curves are being explored in an attempt to reduce bias and improve precision in the
kinetic parameter estimates.  
New reconstruction algorithms for microPET. We developed imaging
reconstruction algorithms for PET, with an emphasis on dynamic PET imaging. We have
completed the development, analysis, and evaluation of a new algorithm for
reconstructing PET images from PET scans that precorrected for random coincidences by
real-time subtraction of delayed-window counts. This subtraction produces negative
sinogram values that are incompatible with the usual Poisson statistical model used in
PET image reconstruction.  The conventional "solution" to this problem, used in some
commercial PET systems, is to set the negatives values to zero and pretend that the data
is Poisson.  Raising negative values to zero can introduce a positive bias in activity
quantification.  We have developed new iterative reconstruction algorithms that account
for the effect of subtracted delayed coincidences and allow for negative sinogram
elements.  Both theoretical analysis and computer simulations show that the new
algorithms avoid the bias of the conventional method yet also have good noise properties.
The computation time of the new method is equivalent to those of existing methods used
clinically, so we have recommended the new methods for routine use for randoms-
precorrected PET scans.
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